CaMab (Camelid VHH)

Development of Camelid monoclonal antibody fragments (CaMab/ VHH ) based immunotherapeutic molecules for infections,  cancers and autoimmune diseases.

The small size (15 kDa), extreme stability, ability to target cryptic antigens and its easy structural manipulations makes it suitable for their use in therapeutic and diagnostic applications.

Libraries are developed against the antigens by immunizing camels and CaMabs with high affinity are isolated using phage display technologies.